These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1578 related items for PubMed ID: 12562575

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, McEvoy J, Cooper TB, Chakos M, Lieberman JA.
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT.
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [Abstract] [Full Text] [Related]

  • 10. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [Abstract] [Full Text] [Related]

  • 11. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
    Meyer JM.
    J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Glucose intolerance with atypical antipsychotics.
    Hedenmalm K, Hägg S, Ståhl M, Mortimer O, Spigset O.
    Drug Saf; 2002 May; 25(15):1107-16. PubMed ID: 12452735
    [Abstract] [Full Text] [Related]

  • 15. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM.
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
    Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL.
    J Child Adolesc Psychopharmacol; 2002 Aug; 12(2):83-91. PubMed ID: 12188977
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N, Foster RH, Olney R, Plosker GL.
    Drugs; 2001 Aug; 61(1):111-61. PubMed ID: 11217867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.